<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448630</url>
  </required_header>
  <id_info>
    <org_study_id>A1281160</org_study_id>
    <nct_id>NCT00448630</nct_id>
  </id_info>
  <brief_title>An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics</brief_title>
  <acronym>MESSAGE</acronym>
  <official_title>A Multi-Center, Non-Interventional, Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find and follow-up the metabolic syndrome parameters on
      patients administering atypical antipsychotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sampling Method Details: Group of patients using the same atypical anti-psychotic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Body Mass Index (BMI)</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative mean Body Mass Index at time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Body Weight</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of body weight. Mean at time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Waist Circumference</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of waist circumference. Mean at timepoints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Fasting Blood Sugar</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of fasting blood sugar. Mean at time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Total Cholesterol</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of total cholesterol. Mean at time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Low Density Lipoprotein (LDL)</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of LDL. Mean at time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter High Density Lipoprotein (HDL)</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of HDL. Mean at time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Syndrome Parameter Triglycerides</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of triglycerides. Mean at time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic Syndrome Parameter BMI by Treatment Group</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of BMI. Mean at time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Syndrome Parameter Weight by Treatment Group</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of weight. Mean at time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Syndrome Parameter Waist Circumference by Treatment Group</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of waist circumference. Mean at time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Syndrome Parameter Triglycerides by Treatment Group</measure>
    <time_frame>Baseline, 1 Month, 4 Months</time_frame>
    <description>Iterative measurement of triglycerides. Mean at time points.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">328</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Atypical Antispychotics (or second generation antipsychotics)</arm_group_label>
    <description>Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Non-interventional study</description>
    <arm_group_label>Atypical Antispychotics (or second generation antipsychotics)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood (fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol,
      triglyceride levels)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female and male patients diagnosed as schizophrenia by DSM-IV (Diagnostic and Statistical
        Manual of Mental Disorders, Fourth Edition) criteria; Age between 18-45 years; Patients who
        started atypical antipsychotic drug treatment or patients who switched from the previous
        conventional or atypical antipsychotic treatment to another atypical antipsychotic drug
        treatment by the decision of their physicians in psychiatry clinics in state and university
        hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients diagnosed as schizophrenia by the Diagnostic and Statistical
             Manual of Mental Disorders.

          -  Age between 18-45 years

          -  Patients who started atypical antipsychotic drug treatment or patients who switched
             from the previous conventional or atypical antipsychotic treatment to another atypical
             antipsychotic drug treatment by the decision of their physicians.

        Exclusion Criteria:

          -  Patients who are pregnant or considering pregnancy.

          -  Patients who were included in a similar study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kurttepe</city>
        <state>Adana</state>
        <zip>01360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Antakya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bolu</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denizli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Elazig</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eskisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trakya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281160&amp;StudyName=An%20Observational%20Study%20On%20Metabolic%20Syndrome%20Parameters%20In%20Schizophrenia%20Patients%20Treated%20With%20Atypical%20Antipsychotics</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <results_first_submitted>July 27, 2009</results_first_submitted>
  <results_first_submitted_qc>June 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2010</results_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <keyword>Atypical antipsychotics, Metabolic syndrome, Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects diagnosed with schizophrenia who have been using or recommended to use atypical antipsychotic drugs.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atypical Antipsychotic Treatment</title>
          <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301">Number of patients who remained on same medication to end of study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atypical Antipsychotic Treatment</title>
          <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="328"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Body Mass Index (BMI)</title>
        <description>Iterative mean Body Mass Index at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Body Mass Index (BMI)</title>
          <description>Iterative mean Body Mass Index at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>kg/m*m (kilograms per meter squared)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>We hypothesize that atypical antipsychotic therapy effects the metabolic syndrome parameters, particularly body mass index.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Syndrome Parameter BMI by Treatment Group</title>
        <description>Iterative measurement of BMI. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>ziprasidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>risperidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine</title>
            <description>quetiapine as prescribed by subject's physician</description>
          </group>
          <group group_id="O4">
            <title>Olanzipine</title>
            <description>olanzipine as prescribed by subject's physician</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole</title>
            <description>aripiprazole as prescribed by subject's physician</description>
          </group>
          <group group_id="O6">
            <title>Amisulpride</title>
            <description>amisulpride as prescribed by subject's physician</description>
          </group>
          <group group_id="O7">
            <title>Other</title>
            <description>other medications not included in the protocol-specified atypical antipsychotic groups: clozapine, haloperidol, zuclopenthixol, sertindole, and sulpiride. Treatment prescribed by subject's physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter BMI by Treatment Group</title>
          <description>Iterative measurement of BMI. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>kg/m*m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.12" spread="18.21"/>
                    <measurement group_id="O2" value="26.17" spread="17.93"/>
                    <measurement group_id="O3" value="26.94" spread="19.82"/>
                    <measurement group_id="O4" value="24.06" spread="18.04"/>
                    <measurement group_id="O5" value="29.76" spread="16.78"/>
                    <measurement group_id="O6" value="24.92" spread="18.25"/>
                    <measurement group_id="O7" value="26.41" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.10" spread="17.28"/>
                    <measurement group_id="O2" value="26.52" spread="18.65"/>
                    <measurement group_id="O3" value="27.70" spread="20.15"/>
                    <measurement group_id="O4" value="24.81" spread="19.05"/>
                    <measurement group_id="O5" value="29.39" spread="16.33"/>
                    <measurement group_id="O6" value="25.12" spread="19.43"/>
                    <measurement group_id="O7" value="26.93" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.19" spread="17.90"/>
                    <measurement group_id="O2" value="27.23" spread="20.08"/>
                    <measurement group_id="O3" value="28.41" spread="21.77"/>
                    <measurement group_id="O4" value="25.39" spread="20.34"/>
                    <measurement group_id="O5" value="28.75" spread="18.34"/>
                    <measurement group_id="O6" value="25.88" spread="20.31"/>
                    <measurement group_id="O7" value="27.76" spread="17.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.490</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0133</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0142</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0265</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1613</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2644</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7385</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6813</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2237</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5774</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2502</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5224</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8166</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Body Weight</title>
        <description>Iterative measurement of body weight. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Body Weight</title>
          <description>Iterative measurement of body weight. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>kg (kilogram)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.27" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.06" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.18" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>We hypothesize that atypical antipsychotic therapy effects the metabolic syndrome parameters, particularly body mass index.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Waist Circumference</title>
        <description>Iterative measurement of waist circumference. Mean at timepoints.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Waist Circumference</title>
          <description>Iterative measurement of waist circumference. Mean at timepoints.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>cm (centimeter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.92" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.07" spread="13.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.80" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time (Baseline, 1 month, 4 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Fasting Blood Sugar</title>
        <description>Iterative measurement of fasting blood sugar. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Fasting Blood Sugar</title>
          <description>Iterative measurement of fasting blood sugar. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>mg/dl (miligrams per deciliter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.82" spread="24.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.64" spread="17.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.79" spread="19.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time (Baseline, 1 month, 4 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.544</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Total Cholesterol</title>
        <description>Iterative measurement of total cholesterol. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Total Cholesterol</title>
          <description>Iterative measurement of total cholesterol. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.48" spread="47.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.81" spread="52.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.67" spread="45.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time (Baseline, 1 month, 4 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.245</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Low Density Lipoprotein (LDL)</title>
        <description>Iterative measurement of LDL. Mean at time points</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Low Density Lipoprotein (LDL)</title>
          <description>Iterative measurement of LDL. Mean at time points</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.71" spread="38.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.56" spread="43.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.86" spread="39.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time (Baseline, 1 month, 4 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter High Density Lipoprotein (HDL)</title>
        <description>Iterative measurement of HDL. Mean at time points</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter High Density Lipoprotein (HDL)</title>
          <description>Iterative measurement of HDL. Mean at time points</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.11" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.99" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.51" spread="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time (Baseline, 1 month, 4 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Syndrome Parameter Triglycerides</title>
        <description>Iterative measurement of triglycerides. Mean at time points</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Atypical Antipsychotic Treatment</title>
            <description>Subjects with schizophrenia treated with the atypical antipsychotic drugs ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, or amisulpride. The requirements of the study did not include inducement for any specific atypical antipsychotic drug. The most appropriate treatment for each subject was decided freely by their doctors.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Triglycerides</title>
          <description>Iterative measurement of triglycerides. Mean at time points</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.11" spread="78.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.46" spread="72.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.63" spread="83.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time (Baseline, 1 month, 4 months).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Syndrome Parameter Weight by Treatment Group</title>
        <description>Iterative measurement of weight. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>ziprasidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>risperidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine</title>
            <description>quetiapine as prescribed by subject's physician</description>
          </group>
          <group group_id="O4">
            <title>Olanzipine</title>
            <description>olanzipine as prescribed by subject's physician</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole</title>
            <description>aripiprazole as prescribed by subject's physician</description>
          </group>
          <group group_id="O6">
            <title>Amisulpride</title>
            <description>amisulpride as prescribed by subject's physician</description>
          </group>
          <group group_id="O7">
            <title>Other</title>
            <description>other medications not included in the protocol-specified atypical antipsychotic groups: clozapine, haloperidol, zuclopenthixol, sertindole, and sulpiride. Treatment prescribed by subject's physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Weight by Treatment Group</title>
          <description>Iterative measurement of weight. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.11" spread="14.10"/>
                    <measurement group_id="O2" value="72.39" spread="12.50"/>
                    <measurement group_id="O3" value="76.22" spread="18.01"/>
                    <measurement group_id="O4" value="69.82" spread="10.72"/>
                    <measurement group_id="O5" value="84.26" spread="20.37"/>
                    <measurement group_id="O6" value="70.68" spread="13.49"/>
                    <measurement group_id="O7" value="74.77" spread="15.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.04" spread="14.11"/>
                    <measurement group_id="O2" value="73.46" spread="13.14"/>
                    <measurement group_id="O3" value="78.41" spread="18.09"/>
                    <measurement group_id="O4" value="71.97" spread="10.23"/>
                    <measurement group_id="O5" value="83.23" spread="19.81"/>
                    <measurement group_id="O6" value="71.02" spread="12.96"/>
                    <measurement group_id="O7" value="76.47" spread="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.43" spread="14.44"/>
                    <measurement group_id="O2" value="75.47" spread="13.37"/>
                    <measurement group_id="O3" value="80.43" spread="17.52"/>
                    <measurement group_id="O4" value="73.68" spread="9.87"/>
                    <measurement group_id="O5" value="81.55" spread="17.24"/>
                    <measurement group_id="O6" value="73.45" spread="13.64"/>
                    <measurement group_id="O7" value="78.54" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.524</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0386</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1976</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2383</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8297</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9081</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7386</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2587</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6263</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2589</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5153</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8952</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Syndrome Parameter Waist Circumference by Treatment Group</title>
        <description>Iterative measurement of waist circumference. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>ziprasidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>risperidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine</title>
            <description>quetiapine as prescribed by subject's physician</description>
          </group>
          <group group_id="O4">
            <title>Olanzipine</title>
            <description>olanzipine as prescribed by subject's physician</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole</title>
            <description>aripiprazole as prescribed by subject's physician</description>
          </group>
          <group group_id="O6">
            <title>Amisulpride</title>
            <description>amisulpride as prescribed by subject's physician</description>
          </group>
          <group group_id="O7">
            <title>Other</title>
            <description>other medications not included in the protocol-specified atypical antipsychotic groups: clozapine, haloperidol, zuclopenthixol, sertindole, and sulpiride. Treatment prescribed by subject's physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Waist Circumference by Treatment Group</title>
          <description>Iterative measurement of waist circumference. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>cm (centimeter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.18" spread="14.62"/>
                    <measurement group_id="O2" value="91.55" spread="13.58"/>
                    <measurement group_id="O3" value="93.75" spread="13.37"/>
                    <measurement group_id="O4" value="89.04" spread="18.95"/>
                    <measurement group_id="O5" value="96.64" spread="15.41"/>
                    <measurement group_id="O6" value="88.80" spread="12.38"/>
                    <measurement group_id="O7" value="94.06" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.42" spread="15.30"/>
                    <measurement group_id="O2" value="93.36" spread="14.50"/>
                    <measurement group_id="O3" value="97.28" spread="14.60"/>
                    <measurement group_id="O4" value="87.57" spread="9.47"/>
                    <measurement group_id="O5" value="96.27" spread="15.72"/>
                    <measurement group_id="O6" value="88.53" spread="10.83"/>
                    <measurement group_id="O7" value="94.89" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.70" spread="14.84"/>
                    <measurement group_id="O2" value="93.52" spread="13.64"/>
                    <measurement group_id="O3" value="97.18" spread="14.46"/>
                    <measurement group_id="O4" value="89.69" spread="8.82"/>
                    <measurement group_id="O5" value="94.92" spread="15.17"/>
                    <measurement group_id="O6" value="90.34" spread="11.82"/>
                    <measurement group_id="O7" value="97.44" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.197</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.282</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0193</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3172</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0116</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2600</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2309</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8158</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3968</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7193</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0127</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2351</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5672</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0,00009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1774</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6082</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5587</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolic Syndrome Parameter Triglycerides by Treatment Group</title>
        <description>Iterative measurement of triglycerides. Mean at time points.</description>
        <time_frame>Baseline, 1 Month, 4 Months</time_frame>
        <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>ziprasidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>risperidone as prescribed by subject's physician</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine</title>
            <description>quetiapine as prescribed by subject's physician</description>
          </group>
          <group group_id="O4">
            <title>Olanzipine</title>
            <description>olanzipine as prescribed by subject's physician</description>
          </group>
          <group group_id="O5">
            <title>Aripiprazole</title>
            <description>aripiprazole as prescribed by subject's physician</description>
          </group>
          <group group_id="O6">
            <title>Amisulpride</title>
            <description>amisulpride as prescribed by subject's physician</description>
          </group>
          <group group_id="O7">
            <title>Other</title>
            <description>other medications not included in the protocol-specified atypical antipsychotic groups: clozapine, haloperidol, zuclopenthixol, sertindole, and sulpiride. Treatment prescribed by subject's physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Syndrome Parameter Triglycerides by Treatment Group</title>
          <description>Iterative measurement of triglycerides. Mean at time points.</description>
          <population>Population : Full Analysis Set. Number of participants analyzed includes subjects with data for each visit.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.89" spread="85.13"/>
                    <measurement group_id="O2" value="129.66" spread="90.13"/>
                    <measurement group_id="O3" value="117.92" spread="80.54"/>
                    <measurement group_id="O4" value="86.24" spread="40.00"/>
                    <measurement group_id="O5" value="113.79" spread="88.12"/>
                    <measurement group_id="O6" value="142.75" spread="83.42"/>
                    <measurement group_id="O7" value="131.88" spread="74.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.25" spread="55.81"/>
                    <measurement group_id="O2" value="121.00" spread="78.34"/>
                    <measurement group_id="O3" value="141.50" spread="78.34"/>
                    <measurement group_id="O4" value="97.48" spread="49.76"/>
                    <measurement group_id="O5" value="111.78" spread="82.98"/>
                    <measurement group_id="O6" value="133.90" spread="67.17"/>
                    <measurement group_id="O7" value="157.38" spread="90.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.04" spread="45.98"/>
                    <measurement group_id="O2" value="148.14" spread="88.69"/>
                    <measurement group_id="O3" value="119.33" spread="55.21"/>
                    <measurement group_id="O4" value="110.97" spread="52.32"/>
                    <measurement group_id="O5" value="127.07" spread="80.83"/>
                    <measurement group_id="O6" value="161.85" spread="143.26"/>
                    <measurement group_id="O7" value="148.00" spread="81.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.593</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.987</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Friedman’s test was used to assess trends over time.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons; p-values &lt; 0.05 were considered statistically significant.</p_value_desc>
            <method>Friedman</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone</title>
          <description>ziprasidone as prescribed by subject's physician</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>risperidone as prescribed by subject's physician</description>
        </group>
        <group group_id="E3">
          <title>Quetiapine</title>
          <description>quetiapine as prescribed by subject's physician</description>
        </group>
        <group group_id="E4">
          <title>Olanzipine</title>
          <description>olanzipine as prescribed by subject's physician</description>
        </group>
        <group group_id="E5">
          <title>Aripiprazole</title>
          <description>aripiprazole as prescribed by subject's physician</description>
        </group>
        <group group_id="E6">
          <title>Amisulpride</title>
          <description>amisulpride as prescribed by subject's physician</description>
        </group>
        <group group_id="E7">
          <title>Other</title>
          <description>other medications not included in the protocol-specified atypical antipsychotic groups: clozapine, haloperidol, zuclopenthixol, sertindole, and sulpiride. Treatment prescribed by subject's physician.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual irregularities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Mouth dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Akathisia + sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Allergy + Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Giddiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dyspahlgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dystasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Epileptic exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Extrapyramidal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyperprolactinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Weight gain + QT extension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Weight gain + Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Late Dischinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Tremor + Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

